Overview

Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer

Status:
RECRUITING
Trial end date:
2031-06-30
Target enrollment:
Participant gender:
Summary
A phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants with Intermediate Risk Non-Muscle Invasive Bladder Cancer (IR NMIBC)
Phase:
PHASE3
Details
Lead Sponsor:
Ferring Pharmaceuticals